| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
To investigate the mechanisms of resistance to hormonal therapy using aromatase inhibitor in postmenopausal breast cancer, we established several estrogen-deprivation-resistant cell lines from xenograft of estrogen receptor-positive human MCF-7 cells transplanted into ovariectomized SCID mice by reflecting clinical microenvironment of estrogen-depleted therapy. Several AI cell lines were isolated from each palpable tumor detected at more than 150 days after transplantation. Most of these cell lines overexpressed ER and some lost ER expression. They showed different expressions of breast cancer stem cell markers and sensitivities to signal cascade inhibitors, suggesting that AI resistant mechanisms might be different for each case.
|
